Pyrrhonian, Bullish Case!Pyrrhonian Monday, 04/28/14 07:56:10 AM Re: sitiain66 post# 9519 Post # of 9524 NW is in a strange position. If IMUC hadn't failed with a very similar sounding vaccine, or was in a pending status trial like NW's, the pps here would be much higher. Perhaps in the high teens-low 20s. But, people are soured. ICT-107, though clear to many here as inferior, showed high Ph I OS (38 months, some two years over SoC) and far less Ph II PFS/OS (just 2 mo over SoC, and stat insig OS of about the same). Very few people out there in the investment world think NW will do much differently. Add that to the oddity of a very outstanding (over 4 months now) DMC rec on efficacy data, and that makes for an uncertain situation with a failed precursor. Who wants any stock in a company like that? Should NW succeed in their Ph III, there could be two hyperbolic price surges. The first may take the price up some 700%-1,000% or more immediately. Then, on day two, the pps would surge again. Short squeeze, margin calls, etc. And an influx of major funds coming on board with a no longer uncertain situation. It could double from its previous day's surge. This is unique, in that NW is quite undervalued to that potential reality. There has been no build up as seen in most Ph IIIs coming downhill to their conclusion. What seems clear to me is that IMUC cherry picked 20 people for their Ph I, like many small biotechs do, and that caused an odd lack of correlation between their PFS and OS. NW went to great lengths to not do so for their 36 (not to mention those in prostate and ovarian trials). They also gave matched control numbers, and their PFS/OS greatly outperformed those. Secondly, IMUC's tech had no real clinical validity elsewhere, whereas NW's had and has (wealth of data out there using whole tumor Lysate). NW will get there before any of these companies with their versions, and if approved, will have marketing exclusivity in US and EUR for 7 and 10 years resp. Besides this, their proprietary methods and formulation seem superior (when comparing public results to date). NW really are forerunners in this space, and while all of the big players were ignoring DC tech in large part, NW was busy perfecting the process and securing various patents. Now, they're locked out. NW has what they cannot get. Neither can they mirror it adequately. It's clear I'm very bullish here, but the main thing that is unknown, still has yet to be proven, and that is clinical results from a Ph III double blind placebo controlled trial. Until that becomes clear, NW's won't go up much, nor stay there for long if they do. © 2014 InvestorsHub.Com, Inc.